# US 2024/0199573 A1 · Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199573 A1
- Document ID: US20240199573A1
- Status: Published application
- Kind: A1
- Application number: 18/347,815
- Filed: 2023-07-06
- Published: 2024-06-20
- Earliest claimed: 2016-06-01
- Assignees: Kalvista Pharmaceuticals Limited
- Applicants: Kalvista Pharmaceuticals Limited
- Inventors: Haydn BEATON; David Malcolm CROWE; Hannah Joy EDWARDS
- Web page: https://patentgrep.com/patent/US20240199573A1

## CPC

- C07D 401/02: containing two hetero rings
- C07D 401/10: linked by a carbon chain containing aromatic rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.

## Claims

### Claim 1

A crystalline form of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl }methyl)pyrazole-4-carboxamide which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 4.7, 9.5, 10.9, 15.3, and 19.9.

### Claim 2 (depends on 1)

The crystalline form of claim 1, which exhibits at least the following additional X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 4.2, 11.4, 14.3, 15.8, 18.6, 21.4, 21.9, 23.0, 23.7, 25.1, 26.5 and 29.3.

### Claim 3 (depends on 1)

The crystalline form of claim 1, which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 4.15, 4.7421, 9.463, 10.8936, 11.4363, 14.2897, 15.28, 15.7912, 18.6355, 19.8599, 21.389, 21.9376, 22.9962, 23.6679, 25.0948, 26.465 and 29.2936.

### Claim 4 (depends on 1)

The crystalline form of claim 1, having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 7.

### Claim 5

A crystalline form of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl) methyl]phenyl }methyl)pyrazole-4-carboxamide which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 5.0, 10.2, 12.7, 14.8, 16.4.

### Claim 6 (depends on 5)

The crystalline form of claim 5, which exhibits at least the following additional X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 10.0, 15.3, 17.5, 19.8, 20.0, 20.6, 24.2, 25.6, 26.8, 27.7 and 35.3.

### Claim 7 (depends on 5)

The crystalline form of claim 5, which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately 5.0236, 10.0456, 10.1526, 12.6705, 14.8188, 15.2588, 16.3621, 17.5026, 19.792, 20.0456, 20.6393, 24.1662, 25.6434, 26.8451, 27.6821 and 35.3459.

### Claim 8 (depends on 5)

The crystalline form of claim 5, having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 8.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a crystalline form of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 10 (depends on 5)

A pharmaceutical composition comprising a crystalline form of claim 5 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 11 (depends on 1)

A method for preparing a pharmaceutical composition comprising combining a crystalline form of claim 1 and one or more pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 12 (depends on 5)

A method for preparing a pharmaceutical composition comprising combining a crystalline form of claim 5 and one or more pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 13 (depends on 1)

A process for preparing the crystalline form of claim 1, comprising crystallising said crystalline form from a mixture of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl) methyl]phenyl}methyl)pyrazole-4-carboxamide in a solvent mixture of isopropanol/water by heating to dissolve the solid and then cooling.

### Claim 14 (depends on 5)

A process for preparing the crystalline form of claim 5, comprising crystallising said crystalline form from a mixture of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl) methyl]phenyl}methyl)pyrazole-4-carboxamide in a solvent mixture of methanol/water and temperature cycling.

### Claim 15 (depends on 1)

A method of treating a disease or condition mediated by plasma kallikrein in a mammal in need of such treatment, said method comprising administering to the mammal a therapeutically effective amount of a crystalline form of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the disease or condition mediated by plasma kallikrein is impaired visual acuity, diabetic retinopathy, retinal vascular permeability associated with diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery, or bleeding from post-operative surgery.

### Claim 17 (depends on 15)

The method of claim 15, wherein the disease or condition mediated by plasma kallikrein is retinal vascular permeability associated with diabetic retinopathy, diabetic macular edema, or hereditary angioedema.

### Claim 18 (depends on 15)

The method of claim 15, wherein the disease or condition mediated by plasma kallikrein is retinal vascular permeability associated with diabetic retinopathy, or diabetic macular edema.

### Claim 19 (depends on 15)

The method of claim 15, wherein the disease or condition mediated by plasma kallikrein is hereditary angioedema.

### Claim 20 (depends on 15)

The method of claim 15, wherein the disease or condition mediated by plasma kallikrein is diabetic macular edema.

### Claim 21 (depends on 15)

The method of claim 15, wherein the disease or condition mediated by plasma kallikrein is retinal vein occlusion.

### Claim 22 (depends on 5)

A method of treating a disease or condition mediated by plasma kallikrein in a mammal in need of such treatment, said method comprising administering to the mammal a therapeutically effective amount of a crystalline form of claim 5.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disease or condition mediated by plasma kallikrein is impaired visual acuity, diabetic retinopathy, retinal vascular permeability associated with diabetic retinopathy, diabetic macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery, or bleeding from post-operative surgery.

### Claim 24 (depends on 22)

The method of claim 22, wherein the disease or condition mediated by plasma kallikrein is retinal vascular permeability associated with diabetic retinopathy, diabetic macular edema, or hereditary angioedema.

### Claim 25 (depends on 22)

The method of claim 22, wherein the disease or condition mediated by plasma kallikrein is retinal vascular permeability associated with diabetic retinopathy, or diabetic macular edema.

### Claim 26 (depends on 22)

The method of claim 22, wherein the disease or condition mediated by plasma kallikrein is hereditary angioedema.

### Claim 27 (depends on 22)

The method of claim 22, wherein the disease or condition mediated by plasma kallikrein is diabetic macular edema.

### Claim 28 (depends on 22)

The method of claim 22, wherein the disease or condition mediated by plasma kallikrein is retinal vein occlusion.
